The advent of COVID-19, has posed a risk that human respiratory samples containing human influenza viruses may also contain SARS-CoV-2. This potential risk may lead to SARS-CoV-2 contaminating conventional influenza vaccine production platforms as respiratory samples are used to directly inoculate embryonated hen’s eggs and continuous cell lines that are used to isolate and produce influenza vaccines. We investigated the ability of these substrates to propagate SARS-CoV-2 and found that neither could support SARS-CoV-2 replication.
All Keywords
【저자키워드】 Influenza, SARS-CoV-2, vaccine, respiratory, air-borne infections, viral infections, influenza, severe acute respiratory syndrome – SARS, influenza virus, biosafety, vaccines and immunisation, laboratory, 【초록키워드】 COVID-19, SARS-CoV-2, Influenza, risk, Influenza virus, platform, SARS-CoV-2 replication, influenza vaccines, Support, potential risk, substrate, cell line, vaccine production, respiratory sample, investigated, 【제목키워드】 SARS-CoV-2, cell line, replicate,
【저자키워드】 Influenza, SARS-CoV-2, vaccine, respiratory, air-borne infections, viral infections, influenza, severe acute respiratory syndrome – SARS, influenza virus, biosafety, vaccines and immunisation, laboratory, 【초록키워드】 COVID-19, SARS-CoV-2, Influenza, risk, Influenza virus, platform, SARS-CoV-2 replication, influenza vaccines, Support, potential risk, substrate, cell line, vaccine production, respiratory sample, investigated, 【제목키워드】 SARS-CoV-2, cell line, replicate,